Vikas Gupta, the CEO of Alkem Laboratories, is expected to leave the company in the next few months, according to sources. Gupta has been at the helm for nearly three years, joining Alkem from Cipla, where he led the India formulations business. His extensive experience includes roles at Glenmark and Ranbaxy, coupled with a medical degree and significant knowledge of the Indian pharmaceutical market. Although Gupta is reportedly being courted by various organizations, including private equity firms, the talks are still ongoing and no confirmation has been made. In a recent interview, Gupta discussed Alkem's strategy to enhance its presence in chronic care products, particularly in cardiac and anti-diabetes sectors. Alkem launched its semaglutide-based weight-loss drugs—Hepaglide, Obesema, and Semasize—on March 21, coinciding with the expiration of the semaglutide patent in India. The company recorded revenues of approximately ₹13,000 crore (roughly $1.56 billion USD) in FY2025-26, with over 70% of that coming from its India operations.